Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment

被引：4
|
作者：
Del Re, Marzia [1 ]
Addeo, Alfredo [2 ]
Passaro, Antonio [3 ]
Petrini, Iacopo [4 ]
van Schaik, Ron H. N. [5 ]
Danesi, Romano [1 ]
机构：
[1] Univ Hosp Pisa, Unit Clin Pharmacol & Pharmacogenet, Dept Clin & Expt Med, Pisa, Italy
[2] Univ Hosp Geneva, Dept Oncol, Geneva, Switzerland
[3] IRCCS, European Inst Oncol, IEO, Div Thorac Oncol, Milan, Italy
[4] Univ Pisa, Gen Pathol, Dept Translat Res & New Technol Surg & Med, Pisa, Italy
[5] Erasmus MC, Dept Clin Chem, Rotterdam, Netherlands
来源：
PHARMACOGENOMICS | 2019年 / 20卷 / 18期
关键词：
circulating biomarkers; EGFR; immunotherapy; NSCLC; predictive biomarkers; MUTATIONS;
D O I：
10.2217/pgs-2019-0150
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：1255 / 1257
页数：3
相关论文
共 50 条
  • [1] Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer
    Kok, Peey-Sei
    Lee, Kirsty
    Lord, Sally
    John, Thomas
    Marschner, Ian
    Wu, Yi-Long
    Mok, Tony S. K.
    Lee, Chen Khoon
    LUNG CANCER, 2022, 163 : 14 - 18
  • [2] Circulating tumour DNA genomics in EGFR-mutant lung adenocarcinoma
    Rosell, Rafael
    Karachaliou, Niki
    LANCET RESPIRATORY MEDICINE, 2018, 6 (09): : 649 - 651
  • [3] Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer
    Cabanero, M.
    Tsao, M. S.
    CURRENT ONCOLOGY, 2018, 25 : S38 - S44
  • [4] Circulating tumor DNA analysis in patients with EGFR mutant lung cancer
    Nanjo, Shigeki
    Bivona, Trever G.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S4061 - S4064
  • [5] Circulating tumor DNA sequencing to reveal the genomic complexity of advanced EGFR-mutant lung adenocarcinoma.
    Blakely, Collin M.
    Banks, Kimberly C.
    Lanman, Richard Burnham
    Riess, Jonathan
    Mack, Philip C.
    Bivona, Trever Grant
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Best Initial Treatment Strategies for EGFR-Mutant Lung Cancer
    Barber, Emily A.
    Reckamp, Karen L.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2016, 12 (12) : 4 - 7
  • [7] New treatment strategy for patients with EGFR-mutant lung cancer
    Ninomiya, Takashi
    Takigawa, Nagio
    Toyooka, Shinichi
    Hotta, Katsuyuki
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    LUNG CANCER MANAGEMENT, 2013, 2 (06) : 505 - 516
  • [8] Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges
    Lim, Jeong Uk
    Jung, Junyang
    Kim, Yeon Wook
    Kim, Chi Young
    Lee, Sang Hoon
    Park, Dong Won
    Choi, Sue In
    Ji, Wonjun
    Yeo, Chang Dong
    Lee, Seung Hyeun
    BIOMEDICINES, 2025, 13 (02)
  • [9] Circulating Tumor DNA Analysis for Predicting Response to Osimertinib and Disease Progression in EGFR-Mutant Non-Small-Cell Lung Cancer
    Kim, C.
    Xi, L.
    Cultraro, C.
    Pham, T.
    Roper, N.
    Bagheri, M.
    Rajan, A.
    Beeler, J.
    Jones, G.
    Raffeld, M.
    Guha, U.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S478 - S478
  • [10] EGFR-Mutant Lung Cancer: New Drugs
    Sequist, Lecia
    ONCOLOGIST, 2013, 18 : S1 - S1
12345